on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics secures its General Meeting
Nantes-based OSE Immunotherapeutics emphasizes its commitment to holding its Annual General Meeting in a transparent and respectful manner. With this in mind, a "Questions and Answers" document has been published online to inform shareholders of recent developments and address misinformation circulating in the market.
In response to resolutions from certain parties seeking to amend the Board of Directors, the General Meeting, initially scheduled for June 25, 2025, was postponed by court order. The new date is September 30, 2025, subject to judicial developments.
Furthermore, OSE Immunotherapeutics has taken legal action to maintain transparency and adherence to market rules, thereby ensuring a constructive exchange with all shareholders during this period of heightened tensions.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news